Trial reportIntensive care medicine2010
Sildenafil attenuates pulmonary arterial pressure but does not improve oxygenation during ARDS.
Trial report in Intensive care medicine, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 50 citations in OpenAlex.
- Pulmonary vascular and right ventricular dysfunction in adult critical care: current and emerging options for management: a systematic literature review.Critical care (London, England) · 2010Pooled it
- Lung-Cardiovascular Interactions and Derangements in ARDS.Comprehensive physiology · 2026Review
- Pulmonary vascular dysfunction in ARDS Pathophysiology and therapeutic implications.Annals of intensive care · 2026Review
- Shunt: pathophysiological mechanisms and clinical implications of ineffective circulating volume.Frontiers in physiology · 2026Review
- Right-sided heart failure in acute respiratory distress syndrome.European respiratory review : an official journal of the European Respiratory Society · 2025Review
- Case report: Inhaled nitric oxide rescued a hypoxemia patient caused by dermatomyositis complicated with interstitial pneumonia.Frontiers in medicine · 2024Article
- Role of Sildenafil in Management of Pediatric Acute Respiratory Distress Syndrome.Journal of pediatric intensive care · 2023Article
- Inhaled Nitric Oxide in Acute Respiratory Distress Syndrome Subsets: Rationale and Clinical Applications.Journal of aerosol medicine and pulmonary drug delivery · 2023Review
- Right ventricule-specific therapies in ARDS: other vasodilating agents to be considered.Critical care (London, England) · 2023Article
- Right ventricle-specific therapies in acute respiratory distress syndrome: a scoping review.Critical care (London, England) · 2023Article
- Pulmonary artery targeted therapy in treatment of COVID-19 related ARDS. Literature review.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2022Review
- Impairment of hypoxic pulmonary vasoconstriction in acute respiratory distress syndrome.European respiratory review : an official journal of the European Respiratory Society · 2021Review
- Phosphodiesterase Inhibitors in Acute Lung Injury: What Are the Perspectives?International journal of molecular sciences · 2021Review
- A Comprehensive Summary of the Knowledge on COVID-19 Treatment.Aging and disease · 2021Review
- Acute lung injury - from pathophysiology to treatment.Physiological research · 2020Review
- Effect of Coronavirus Disease 2019 in Pulmonary Circulation. The Particular Scenario of Precapillary Pulmonary Hypertension.Diagnostics (Basel, Switzerland) · 2020Review
- Management of acute right ventricular failure in the intensive care unit.Annals of the American Thoracic Society · 2014Review
- Cardiopulmonary interactions during mechanical ventilation in critically ill patients.Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation · 2013Article
- Haemodynamic and neuroendocrine effects of tezosentan in chronic experimental pulmonary hypertension.Intensive care medicine · 2012Article
- Pathophysiology of pulmonary hypertension in acute lung injury.American journal of physiology. Lung cellular and molecular physiology · 2012Review
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivePulmonary hypertension is a characteristic feature of acute respiratory distress syndrome (ARDS) and contributes to mortality. Administration of sildenafil in ambulatory patients with pulmonary hypertension improves oxygenation and ameliorates pulmonary hypertension. Our aim was to determine whether sildenafil is beneficial for patients with ARDS.
designProspective, open-label, multicenter, interventional cohort study.
settingMedical-surgical ICU of two university hospitals. PATIENTS: Ten consecutive patients meeting the NAECC criteria for ARDS.
interventionsA single dose of 50 mg sildenafil citrate administered via a nasogastric tube. MAIN
resultsAdministration of sildenafil in patients with ARDS decreased mean pulmonary arterial pressure from 25 to 22 mmHg (P = 0.022) and pulmonary artery occlusion pressure from 16 to 13 mmHg (P = 0.049). Systemic mean arterial pressures were markedly decreased from 81 to 75 mmHg (P = 0.005). Sildenafil did not improve pulmonary arterial oxygen tension, but resulted in a further increase in the shunt fraction.
conclusionAlthough sildenafil reduced pulmonary arterial pressures during ARDS, the increased shunt fraction and decreased arterial oxygenation render it unsuitable for the treatment of patients with ARDS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.